Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL4222853 | 0.96 | OPRM1 (0.79) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL14320307 | 0.96 | OPRM1 (0.79) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxymorphone SCHEMBL7049111 | 0.94 | OPRM1 (0.77) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Naloxone SCHEMBL1702631 | 0.92 | OPRK1 (0.69) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL19285728 | 0.92 | OPRM1 (0.61) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL17165053 | 0.92 | OPRM1 (0.61) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxymorphone SCHEMBL6341083 | 0.91 | OPRM1 (0.68) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL19463262 | 0.90 | OPRM1 (0.59) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL1360634 | 0.89 | OPRM1 (0.91) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Hydrocodone SCHEMBL1360903 | 0.89 | OPRM1 (0.89) | OPRM1OPRD1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430897-A2 | Opioid formulations having extended controlled release | EURO-CELTIQUE S.A. (LU) | 2004-06-23 | — | — | EP | claimed |
| US-20180000942-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-01-04 | — | — | US | disclosed |
| EP-2719378-A1 | Pharmaceutical compositions | Alpharma Pharmaceuticals LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130142845-A1 | USE OF A COMBINATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST FOR THE TREATMENT OF CROHN'S DISEASE AND THE SYMPTOMS ASSOCIATED WITH CROHN'S DISEASE | EURO-CELTIQUE S.A. (LU) | 2013-06-06 | — | — | US | disclosed |
| EP-2263673-A1 | Opioid formulations having extended controlled release | EURO-CELTIQUE S.A. (LU) | 2010-12-22 | — | — | EP | disclosed |
| EP-1430897-A3 | Opioid formulations having extended controlled release | EURO-CELTIQUE S.A. (LU) | 2004-07-14 | — | — | EP | disclosed |
| EP-1430897-A2 | Opioid formulations having extended controlled release | EURO-CELTIQUE S.A. (LU) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000942-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | OPRM1 2050/4885OPRD1 3158/4885OPRK1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.